Gogo's loan extension and decade-long spectrum renewal offer concrete catalysts, while Galileo adoption must translate into stronger overall financial results.
Read the story
Erayak's manufacturing and hybrid-power update provides a concrete catalyst, while commercial launches, margins and cash conversion remain the next tests.
SunCar's preliminary nine-month profit forecast and new repurchase authorization provide two concrete catalysts, with cash conversion and buyback execution still to prove.
Annovis Bio's share-and-warrant offering raises funding while adding ownership pressure, against the backdrop of a recent NYSE compliance notice.
SANUWAVE faces a roughly 21% physician-office reimbursement reduction for 2027, while higher hospital payments offer a partial counterweight.
Elong Power's $3.26 million warrant agreement offers fresh funding while adding shares and potential future dilution after a volatile trading reversal.
ThredUp's holiday-quarter revenue forecast missed expectations, putting profitability and analyst downgrades in focus after a sharp selloff.
Teads' weak quarter combines falling revenue, negative adjusted EBITDA and substantial debt; its large noncash impairment must be separated from cash burn.
A revenue miss, weaker outlook and sales-team disruption explain why MNTN's growing earnings failed to reassure investors.
Fluent's growing commerce-media business explains why its next earnings release deserves attention, but losses and financing risk remain central.
A long-term Marc Jacobs license strengthens Coty's brand story while first-quarter results show why investors should distinguish core-brand growth from division-wide performance.
Record quarterly revenue and stronger margins give Arq a tangible earnings story, while restricted cash remains an important qualification.